Takeda Pharmaceuticals has entered an agreement with Osaka University to develop the practical application and commercialization of vaccines using immune boosting nanoparticles. The three-year partnership also establishes a Joint Research Chair at Osaka University and will focus on creating joint research ventures with local businesses. Takeda seeks to utilize fundamental nanoparticle technology developed at Osaka University and combine it with their knowledge of the pharmaceutical development process. Nanoparticles have shown that they can efficiently carry and deliver antigens throughout the body and Takeda believes that they can become a beneficial tool in the prevention of infectious diseases.
News and Analysis
Be the first to comment.
Follow Patexia.
